The clinical features of pulmonary artery involvement in Takayasu arteritis and its relationship with ischemic heart diseases and infection

Table 2 Clinical features and treatments of the patients complicate with NTM infection

Case	PAI	Age, gender	Species	Type	Treatment when infection was diagnosed	Maximum PSL dose	TAK disease duration (months) at diagnosis of NTM	Treatments for NTM
1	Yes	30F	M. avium	FC	PSL 15 mg	60	41	RFP, EB, CAM, SM, and operation
2	Yes	55F	M. avium	FC	PSL 7 mg, TCZ 162 mg s.c./week	40	241	RFP, EB, CAM
3	Yes	31F	M. avium	FC	PSL 5 mg, MTX 8 mg/w, TCZ 8 mg/kg DIV/4 weeks	20	71	RFP, EB, CAM, SM, and operation
4	Yes	72F	M. intracellulare	NB	PSL 2.5 mg	20	592	Observation
5	Yes	42F	Not identified	NB	PSL 12.5 mg	30	69	RFP, EB, CAM
6	No	64F	M. intracellulare	NB	PSL 5 mg	30	33	Observation

PAI pulmonary artery involvement, NTM nontuberculous mycobacteria, PSL predonisolone (mg/day), TAK Takayasu arteritis, F female, M. avium mycobacterium avium, M. intracellulare mycobacterium intracellulare, FC fibrocavitary type, NB nodular/bronchiectatic type, PSL prednisolone, TCZ tocilizumab, MTX methotrexate, s.c subcutaneous infusion, DIV drip infusion in vein, RFP rifampicin, EB ethambutol, CAM clarithromycin, SM streptomycin

ISSN: 1478-6362